Eli Lilly's weight loss drug retatrutide clears first late-stage study

December 11, 2025

•

1 min read

•

cnbc.com

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.

Eli Lilly on Thursday said its next-generation obesity drug delivered what appears to be the highest weight loss yet in a late-stage trial while reducing knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. The... [2962 chars]

Read Original Article

Source: cnbc.com

Visit Source

Share this article

Twitter Facebook

Back to business news